US Stock Movement: Tempus AI surged on October 20 with AI pre-screening for non-small cell lung cancer and biomarker detection
Bitget异动解读2026/10/20 16:45Tempus AI Soars on October 20: Analysis
Keywords: AI pre-screening for non-small cell lung cancer, biomarker testing
On October 19, Tempus announced results from an AI-assisted pre-screening study for advanced non-small cell lung cancer: analyzing 60,459 cases and involving 12 types of biomarkers, with all sensitivities exceeding 80% using standard H&E pathological images, and several surpassing 90%. The study results will be presented at the 2026 European Society for Medical Oncology Congress.
(Disclaimer: This content is generated by AI technology summarizing public information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crypto prices
More
